KYTX
NASDAQ · Biotechnology
Kyverna Therapeutics Inc
$7.94
-0.60 (-7.03%)
Open$8.16
Previous Close$8.54
Day High$8.44
Day Low$7.91
52W High$13.67
52W Low$1.78
Volume—
Avg Volume560.7K
Market Cap462.75M
P/E Ratio—
EPS$-3.72
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+2.8% upside
Current
$7.94
$7.94
Target
$8.16
$8.16
$5.68
$8.16 avg
$10.96
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.52M | 81.06M | 62.85M |
| Net Income | -14,424,701 | -12,557,463 | -9,873,224 |
| Profit Margin | -18.6% | -15.5% | -15.7% |
| EBITDA | -20,391,428 | -20,108,436 | -16,996,352 |
| Free Cash Flow | -5,835,314 | -8,946,067 | -4,753,485 |
| Rev Growth | +5.4% | +22.1% | -7.0% |
| Debt/Equity | 0.25 | 0.20 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |